Related Experiment Video
Updated: May 30, 2025
06:27
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
2.5K
Brazilian Dialysis Survey 2023
Fabiana B Nerbass1, Helbert do Nascimento Lima2, Jorge P Strogoff-de-Matos3,4
1Fundação Pró-Rim, Joinville, SC, Brazil.
Jornal Brasileiro De Nefrologia
|January 29, 2025
Summary
The number of Brazilians on dialysis is rising, with 157,357 patients in 2023. Hemodiafiltration and specific medications for hyperparathyroidism are increasingly used, while the mortality rate remains significant.
Area of Science:
- Nephrology
- Epidemiology
- Public Health
Background:
- The annual Brazilian Dialysis Survey (BDS) is crucial for informing national health policies.
- This study presents the 2023 epidemiological data from the BDS.
Purpose of the Study:
- To report the 2023 epidemiological data collected by the Brazilian Society of Nephrology's annual survey.
- To provide insights into the prevalence, incidence, and treatment trends in chronic dialysis patients in Brazil.
Main Methods:
- A voluntary online questionnaire was administered to Brazilian chronic dialysis centers.
- Data on patient demographics, clinical aspects, and center characteristics were collected.
- Estimates for prevalence and incidence utilized a random sample of 124 dialysis centers.
Main Results:
- An estimated 157,357 patients were on dialysis in Brazil as of July 1, 2023, with a prevalence rate of 771 pmp.
- The incidence rate was 251 pmp, with 51,153 new patients starting dialysis in 2023.
- Hemodialysis was the predominant treatment (88.2%), followed by hemodiafiltration (8.0%) and peritoneal dialysis (3.8%). Anemia affected 29% and hyperphosphatemia 30% of patients. Usage of cinacalcet and paricalcitol increased. The crude annual mortality rate was 16.2%.
Conclusions:
- The absolute number and prevalence rate of patients undergoing chronic dialysis in Brazil continue to increase.
- There is a notable rise in the adoption of hemodiafiltration and the use of cinacalcet and paricalcitol for managing hyperparathyroidism.
